Related Experiment Video

Updated: Jun 2, 2026

Live Imaging to Quantify Cellular Radiosensitivity in Patient-Derived Tumor Organoids
05:39

Live Imaging to Quantify Cellular Radiosensitivity in Patient-Derived Tumor Organoids

Published on: April 5, 2024

Current state of knowledge regarding the use of antiangiogenic agents with radiation therapy

Renaud Mazeron1, Bethany Anderson, Stéphane Supiot

  • 1Radiation Oncology, Institut Gustave Roussy, Villejuif Cedex, France.

Cancer Treatment Reviews
|May 7, 2011
PubMed

Insights

Targeted antiangiogenic agents show promise for cancer treatment when combined with radiation therapy. Early clinical trials suggest encouraging results, though no agent is yet approved for this combination therapy.

Area of Science:

  • Oncology
  • Vascular Biology
  • Radiation Oncology

Background:

  • Angiogenesis is crucial in cancer development and progression.
  • Antiangiogenic agents target tumor blood vessel formation.
  • Current antiangiogenic therapies lack approval for combined use with radiotherapy.

Purpose of the Study:

  • To review targeted antiangiogenic agents.
  • To summarize early clinical results of combining these agents with radiation therapy.

Main Methods:

  • Review of preclinical studies.
  • Analysis of early-phase clinical trials.

Main Results:

  • Preclinical data and small clinical trials show encouraging outcomes.
  • No antiangiogenic agent is currently approved for combination with radiotherapy.

Conclusions:

  • Targeted antiangiogenic agents represent a promising strategy in oncology.
  • Further clinical investigation is warranted for combination therapy with radiation.

More Related Videos

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...